In his weekly clinical update, Dr. Griffin informs us about mpox circulation, the Marburg virus outbreak in Rwanda, new recommendations for the RSV and pneumococcal vaccines by the CDC, the beginning of influenza season, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, contrasting public health concerns between the US and the UK, what the risk of SARS-CoV-2 transmission is when indoors, the difference between NVX-CoV2327 and BNT162b2 for adolescents, why 65 years and older should get a second boost of the COVID-19 vaccine, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, the clinical trial for evaluating how novel treatments of COVID-19 affect long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome after SARS-CoV-2 infection.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Grim marker: mpox over a 1000 deaths in Africa (CIDRAP)
• Global trend of mpox outbreak 2022-2024 (WHO)
• Second time mpox is a global public health emergency (Reuters)
• Mpox variant in Germany (Reuters)
• Epidemiological analysis of confirmed mpox cases in Burundi (EuroSurveillance)
• The 63rd case of Marburg virus infections in Rwanda (CIDRAP)
• How to stop Marburg virus (Rwanda Biomedical Centre)
• Marburg virus fact sheet (Rwanda Biomedical Centre)
• FDA approves RSV vaccine ABRYSVO for 18-59 individuals of increased risk (Pfizer)
• Respiratory syncytial virus infection-NET (CDC)
• New pneumococcal vaccine recommendations…..it's a virus? (CDC Newsroom)
• Recommending PREVNAR 20, 20 valent pneumococcal conjugate vaccine for 50 and over (Pfizer)
• And one more, CAPVEXIVE, pneumococcal 21 valent conjugate vaccine (Merck)
• Penumococcoal 21-valent conjugate vaccine CAPVEXIVE(MerckVaccines.com)
• Influenza surveillance: Key updates (CDC)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• Waste water scan for 11 pathogens (WastewaterSCan)
• What is happening across the pond? (UKHSA data dashboard)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Risk of SARS-CoV-2 transmission when indoors (JID)
• NVX-CoV2327 vs BNT162b2 vaccines in adolescents (Pediatric Infectious Disease Journal)
• Second dose of 2024-2025 COVID19 vaccine recommended for 65 and older (CDC Newsroom)
• New preventive COVID-19 agent (ISDA)
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Viral and symptom rebound following monoclonal antibody therapy (JID)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• ASH living guidelines on use of anticoagulation for thromboprophylaxis in patients with COVID-19: executive summary, Dr. Daniel Griffin (Blood Advances)
• Novel treatments for acute COVID-19 should account for long COVID (JID) The persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) after SARS-CoV-2 infection (Journal of Infection)
• Letters read on TWiV 1160
• Dr. Griffin's COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]